Demonstrating that MTD performance is associated with continuous measures of amyloid, tau, neurodegeneration, and vascular injury is in line with the Alzheimer’s Association research framework for biological diagnosis of AD (18) (currently under revision), as well. The gene discussed is MAPT; the disease is Alzheimer disease.